Special Issue "Vaccine Development Needs for Marburg Virus and Sudan Ebolavirus: Leveraging Lessons Learned from the Zaire Ebolavirus"
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 2487
Interests: biodefense; vaccines; immunology; vaccine manufacturing; clinical trials
Interests: vaccine development; biodefense pathogens and emerging infectious diseases; preclinical testing
Interests: vaccine development; biodefense pathogens and emerging infectious diseases; preclinical testing; immunology; immune assays
Interests: animal model; vaccine and advanced product development; biodefense; immunology; microbiology
Since 2014, we have seen dramatic progress in the field of Ebola vaccines, largely driven by the urgent need associated with the 2014–2016 epidemic in West Africa. The collective efforts from the filovirus community resulted in vaccines moving from preclinical development to a licensed vaccine by the end of 2019. However, the licensed vaccine protects only against Zaire ebolavirus and other related viruses (specifically Sudan ebolavirus and Marburg virus) still pose urgent threats.
The recent outbreak of Marburg virus highlights the urgent need for vaccines that could be used to help slow the spread of disease when these outbreaks inevitably occur. It also casts a light on our collective level of preparedness in terms of available medical countermeasures.
In this Special Issue, we aim to cover lessons learned from the Zaire ebolavirus vaccine development, and how this can/will be applied to vaccine development for Sudan ebolavirus and Marburg virus. Topics will include perspectives from the USG and product developers on the development of Zaire ebolavirus vaccines, challenges and lessons learned, regulatory strategies, and updates of licensed or lead candidates. Other topics will include the development of standardized tools, such as available immunological assays and animal models, and clinical trial network operations during outbreaks. The goal is to provide an overview of the current status of Marburg virus and Sudan ebolavirus vaccines and some of the key enabling technologies.
Dr. Daniel Wolfe
Dr. Kimberly L. Taylor
Dr. Lawrence A. Wolfraim
Dr. Clint Florence
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.